Avanir Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AVNR)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Avanir Pharmaceuticals (NASDAQ:AVNR)

Avanir Pharmaceuticals logoAVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Receive AVNR News and Ratings via Email

Sign-up to receive the latest news and ratings for AVNR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Avanir Pharmaceuticals (NASDAQ:AVNR) Frequently Asked Questions

What is Avanir Pharmaceuticals' stock symbol?

Avanir Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVNR."

Who are some of Avanir Pharmaceuticals' key competitors?

How do I buy Avanir Pharmaceuticals stock?

Shares of Avanir Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Avanir Pharmaceuticals?

Avanir Pharmaceuticals' mailing address is 20 Enterprise Ste 200, ALISO VIEJO, CA 92656-7104, United States. The healthcare company can be reached via phone at +1-949-3896700.

MarketBeat Community Rating for Avanir Pharmaceuticals (AVNR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about Avanir Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Avanir Pharmaceuticals (NASDAQ:AVNR) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Avanir Pharmaceuticals (NASDAQ:AVNR) Earnings History and Estimates Chart

Earnings by Quarter for Avanir Pharmaceuticals (NASDAQ:AVNR)

Avanir Pharmaceuticals (NASDAQ AVNR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/10/2014Q4 2014($0.05)($0.08)$32.63 million$32.71 millionViewN/AView Earnings Details
8/5/2014Q314($0.08)($0.08)$29.46 million$28.60 millionViewListenView Earnings Details
5/6/2014Q214($0.08)($0.08)$28.21 million$26.95 millionViewListenView Earnings Details
2/5/2014Q114($0.08)($0.07)$24.84 million$26.70 millionViewListenView Earnings Details
12/10/2013Q4($0.07)($0.24)$21.86 million$21.70 millionViewListenView Earnings Details
8/6/2013Q3 2013($0.11)($0.08)$19.53 million$19.80 millionViewListenView Earnings Details
5/8/2013Q2 2013($0.09)($0.12)$17.40 million$17.40 millionViewListenView Earnings Details
2/7/2013Q1 2013($0.09)($0.09)$7.20 million$16.50 millionViewListenView Earnings Details
12/12/2012Q4 2012($0.08)($0.09)ViewN/AView Earnings Details
8/8/2012($0.11)($0.11)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/7/2012($0.13)($0.12)ViewN/AView Earnings Details
12/12/2011($0.16)($0.14)ViewN/AView Earnings Details
8/8/2011($0.13)($0.13)ViewN/AView Earnings Details
5/9/2011($0.14)($0.12)ViewN/AView Earnings Details
2/3/2011($0.14)($0.11)ViewN/AView Earnings Details
11/30/2010Q4 2010($0.10)($0.10)ViewN/AView Earnings Details
8/5/2010Q3 2010($0.07)($0.06)ViewN/AView Earnings Details
5/3/2010Q2 2010($0.07)($0.08)ViewN/AView Earnings Details
11/24/2009Q4 2009($0.09)ViewN/AView Earnings Details
7/29/2009Q3 2009($0.06)ViewN/AView Earnings Details
5/7/2009Q2 2009($0.06)ViewN/AView Earnings Details
2/17/2009Q1 2009($0.07)ViewN/AView Earnings Details
2/7/2009Q1 2010($0.06)ViewN/AView Earnings Details
12/15/2008Q4 2008($0.07)ViewN/AView Earnings Details
8/7/2008Q3 2008($0.02)ViewN/AView Earnings Details
5/13/2008Q2 2008($0.12)ViewN/AView Earnings Details
2/7/2008Q1 2008($0.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Avanir Pharmaceuticals (NASDAQ:AVNR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com


Dividend History for Avanir Pharmaceuticals (NASDAQ:AVNR)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Avanir Pharmaceuticals (NASDAQ AVNR) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Avanir Pharmaceuticals (NASDAQ:AVNR)

Avanir Pharmaceuticals (NASDAQ AVNR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2014Christine OcampoVPSell35,780$16.94$606,113.20View SEC Filing  
12/18/2014Joao Md SiffertSVPSell15,505$16.93$262,499.65View SEC Filing  
12/17/2014Keith KatkinCEOSell277,680$16.95$4,706,676.00View SEC Filing  
11/28/2014Rohan PalekarSVPSell15,000$15.00$225,000.00View SEC Filing  
10/24/2014Christine OcampoVPSell2,080$11.81$24,564.80View SEC Filing  
10/24/2014Joao Md SiffertSVPSell8,426$11.80$99,426.80View SEC Filing  
10/24/2014Keith KatkinCEOSell27,567$11.76$324,187.92View SEC Filing  
9/15/2014Christine OcampoVPSell55,000$9.45$519,750.00View SEC Filing  
9/15/2014Rohan PalekarSVPSell25,000$11.50$287,500.00View SEC Filing  
8/1/2014Keith KatkinCEOSell9,670$5.26$50,864.20View SEC Filing  
5/16/2014Christine OcampoVPSell37,496$5.05$189,354.8081,981View SEC Filing  
12/17/2013Rohan PalekarSVPBuy10,000$2.80$28,000.00143,000View SEC Filing  
11/4/2013Rohan PalekarSVPBuy10,000$4.19$41,900.00View SEC Filing  
9/18/2013Joao Md SiffertSVPSell21,094$4.22$89,016.68116,200View SEC Filing  
8/2/2013Keith KatkinCEOSell15,500$4.84$75,020.00View SEC Filing  
5/15/2013Christine OcampoVPSell77,700$3.29$255,633.00View SEC Filing  
5/15/2013Keith KatkinCEOSell250,438$3.26$816,427.88View SEC Filing  
12/13/2012Rohan PalekarSVPBuy10,000$2.46$24,600.00View SEC Filing  
12/3/2012Christine OcampoVPSell2,845$2.55$7,254.75View SEC Filing  
12/3/2012Keith KatkinCEOSell18,250$2.55$46,537.50View SEC Filing  
(Data available from 1/1/2013 forward)


Avanir Pharmaceuticals (NASDAQ AVNR) News Headlines


SEC Filings

Avanir Pharmaceuticals (NASDAQ:AVNR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Avanir Pharmaceuticals (NASDAQ:AVNR) Income Statement, Balance Sheet and Cash Flow Statement


Avanir Pharmaceuticals (NASDAQ AVNR) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.